Studies have recently shown SARS-CoV-2 present in stool of infected patients, suggesting transmission risk
WEDNESDAY, March 25, 2020 (HealthDay News) — The U.S. Food and Drug Administration issued a MedWatch Safety Alert on Tuesday about the potential risk for SARS-CoV-2 transmission with the use of fecal microbiota for transplantation (FMT) to treat Clostridioides difficile infection.
Recent data have shown that SARS-CoV-2 RNA and/or the SARS-CoV-2 virus is present in the stool of patients with the novel coronavirus (COVID-19), suggesting that SARS-CoV-2 could be transmitted by FMT. Testing of nasopharyngeal specimens from stool donors for SARS-CoV-2 is not widely available at this time, so information on the sensitivity of directly testing stool for SARS-CoV-2 is limited.
The FDA directed health care workers to implement the following protections for any FMT with stool donated after Dec. 1, 2019: conduct donor screening to identify donors who may be or recently could have been infected with SARS-CoV-2; test donors and/or donor stool for SARS-CoV-2; develop criteria for excluding donors and donor stool based on screening and testing; and obtain informed consent from patients regarding the potential for transmission of SARS-CoV-2 via FMT, including FMT prepared from the stool of donors who are asymptomatic for COVID-19.
The FDA requests that any adverse events or side effects related to the use of FMT be reported to the MedWatch Safety Information and Adverse Event Reporting Program.
Health News Copyright © 2020 HealthDay. All rights reserved.
